Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.

You may also be interested in...



AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug

Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.

AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug

Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.

Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD Is The Likely Culprit

Abbott and AstraZeneca aren't providing any details about why the FDA issued a "complete response" letter for their cholesterol-lowering combo drug Certriad (rosuvastatin/fenofibric acid delayed release). But given that the fixed-dose combination pill combines two already marketed drugs - AstraZeneca's statin Crestor and Abbott's triglyceride-lowering medication TriLipix - it's likely the agency's concerns have more to do with efficacy than safety

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel